Printer Friendly

HYAL BEGINS CLINICAL EVALUATION OF A SECOND INDICATION FOR ITS TOPICAL SKIN CANCER PRODUCT

 MISSISSAUGA, Ontario, Sept. 15 /PRNewswire/ -- Hyal Pharmaceutical Corporation (NASDAQ-NMS: HYALF) announced today that approval has been received from Health Protection Branch in Canada to proceed with a clinical evaluation of HYAL-CT1101 in the treatment of Actinic Keratosis (AK).
 Currently in Phase III evaluation in Australia, Canada and the United States for the treatment of basal cell carcinoma (BCC), this new trial will assess the safety and effectiveness of HYAL-CT1101 in a second indication, namely Actinic Keratosis (AK).
 Believed to have an incidence rate of 2-3 times that of BCC, AK or Solar Keratosis as it is known in some countries, is a sun-induced, precancerous skin condition which unlike BCC also affects non-Caucasian skin types. Currently available topical products for the treatment of this condition are associated with severe toxic side affects. Preliminary experience with HYAL-CT1101 in the treatment of AK has demonstrated that the product is effective without causing the redness and peeling of skin associated with the currently available topical therapies.
 The trial will commence in Vancouver at the University of British Columbia, Department of Dermatology.
 Hyal specializes in the development and world wide commercialization of pharmaceutical formulations utilizing its proprietary Hyaluronic Acid based drug delivery technology. Hyal is currently conducting Phase III clinical trials at 20 independent centers in Canada, the U.S.A., Australia and a number of European countries for its three lead products; HYAL-CT1101 for the treatment of basal cell carcinoma, HYAL- AT2101 for the topical treatment of pain and HYAL-AV2201 for the intravenous treatment of moderate to severe pain.
 Hyal Pharmaceutical Corporation's shares are traded on the Toronto Stock Exchange under the trading symbol HPC and on NASDAQ National Market System under the trading symbol HYALF.
 -0- 9/15/93
 /CONTACT: Samuel S. Asculai, president & CEO, 416-366-4863, or David W. Harper, VP - development, 416-366-4863, both of Hyal Pharmaceutical; Diane Perry (New York), 212-661-8030, or Kathy Brunson (Chicago), 312-266-7800, both of Financial Relations Board/
 -0- 9/15/93
 (HYALF HPC.)


CO: Hyal Pharmaceutical Corporation ST: Ontario IN: MTC SU:

SH -- NY018 -- 2110 09/15/93 09:39 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 15, 1993
Words:343
Previous Article:LAMIVUDINE: EARLY PHASE II TRIAL RESULTS ENCOURAGING; LATE PHASE II TRIALS INITIATED
Next Article:BIOMEDICAL SENSORS BEGINS DISTRIBUTION OF PARATREND 7
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters